^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Apoptosis inhibitor

    Related drugs:
    Apply
    A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (KEYNOTE-A10) (NCT03058289)
    Phase 1/2
    Intensity Therapeutics, Inc.
    Completed
    Last update posted :
    08/13/2024
    Initiation :
    02/09/2017
    Primary completion :
    02/22/2023
    Completion :
    02/22/2023
    MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • cisplatin/vinblastine/SHAO-FA (INT230-6)
    Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer (EPIcol) (NCT06147960)
    Phase N/A
    Centre Hospitalier Universitaire de Nīmes
    Not yet recruiting
    Last update posted :
    11/28/2023
    Initiation :
    11/01/2023
    Primary completion :
    05/01/2024
    Completion :
    11/01/2024
    BIRC3 • XIAP
    Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis (I-HEP) (NCT04810156)
    Phase 2
    Inge Marie Svane
    Recruiting
    Last update posted :
    12/14/2022
    Initiation :
    04/07/2021
    Primary completion :
    04/07/2025
    Completion :
    11/07/2025
    PD-L1
    |
    methylprednisolone sodium succinate
    INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer (NCT04781725)
    Phase 2
    Ottawa Hospital Research Institute
    Recruiting
    Last update posted :
    11/17/2021
    Initiation :
    03/25/2021
    Primary completion :
    03/01/2022
    Completion :
    03/01/2023
    CD8 • CD4
    |
    cisplatin • cisplatin/vinblastine/SHAO-FA (INT230-6)
    Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia (NCT01097304)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    12/19/2017
    Initiation :
    04/01/2010
    Primary completion :
    04/01/2014
    Completion :
    07/01/2014
    MKI67
    Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer (NCT02715882)
    Phase 2
    BioLab 612 LLC
    Unknown status
    Last update posted :
    02/09/2017
    Initiation :
    11/01/2015
    Primary completion :
    02/01/2017
    Completion :
    12/31/2017
    IL6 • CXCL8 • IL10
    |
    entolimod (STAT-600)